Brilaroxazine, Reviva Pharmaceuticals’ experimental therapy for idiopathic pulmonary fibrosis (IPF), was found to reduce lung inflammation and fibrosis, or scarring, in a rat model of the disease. The treatment also improved lung function and extended survival in the animals, the study showed. Titled “Evaluation of Brilaroxazine (RP5063)…
Treatment with brilaroxazine found to ease lung scarring in IPF rat model
Cumberland Pharmaceuticals is launching a Phase 2 clinical trial to assess the safety and efficacy of its investigational therapy, ifetroban, in treating patients with idiopathic pulmonary fibrosis (IPF). The announcement follows the U.S. Food and Drug Administration (FDA)…
My name is Sam, and I read a lot. I enjoy reading. I’m not asking for help or seeking an intervention. I read a wide variety of material and have favorites across many different genres. In the fiction category, I enjoy the Mitch Rapp series, originally by Vince Flynn. In…
Dosing is now complete in the Phase 2b GALACTIC-1 trial of GB0139 for treating idiopathic pulmonary fibrosis (IPF). The trial, which finished enrolling participants about a year ago, is testing the safety and effectiveness of the inhaled treatment candidate against a placebo among IPF patients who are…
An experimental oral medication Bristol Myers Squibb is developing did better than a placebo at slowing lung function decline for up to 26 weeks, slightly more than six months, in people with idiopathic pulmonary fibrosis (IPF). The effect was seen when the therapy, BMS-986278, was given at a…
Researchers have discovered a variant of the usual basal stem cells found in the lungs that may contribute to scarring, or fibrosis, in people with idiopathic pulmonary fibrosis (IPF) — and which may be a therapeutic target to slow disease progression. The team found that these basal stem cells,…
Have you ever tried to explain to someone who has never experienced a rare disease how patients can develop lasting relationships with their care team? I have, and it’s often met with skepticism. Many people see their physicians only once or twice a year. But that isn’t the case for…
patientMpower and Qureight have joined forces to accelerate the discovery of new prognostic markers for interstitial lung diseases (ILDs), a group of lung diseases characterized by scarring and inflammation that includes idiopathic pulmonary fibrosis (IPF). The collaboration will harness Qureight’s artificial intelligence (AI) capability along with patientMpower’s…
When I first began experiencing symptoms of idiopathic pulmonary fibrosis (IPF), my condition worsened quickly and kept me from doing many activities I enjoyed. And yet, it took 13 months for me to receive a diagnosis. This time frame felt like an eternity and left me and…
Dosing is complete in the Phase 3 REBUILD clinical trial testing INOpulse (inhaled nitric oxide) in people with pulmonary fibrosis at risk of developing pulmonary hypertension. In the blinded part of the study, which is now complete, participants were randomly assigned to receive nitric oxide or a placebo administered…
